Latest Conference Articles

Study finds 86.5% of gastric/GEJ patients completed surgery after neoadjuvant chemo, significantly improving survival over those who did not.

Long-term data show watch-and-wait is viable for rectal cancer, with most regrowths salvageable despite adverse baseline MRI features.

A real-world study presented at ESMO GI shows fruquintinib is effective in mCRC, with the best outcomes in the third-line setting.

Maite San Miguel and a new survey highlight how specialized training and clinical autonomy are vital for optimizing multiple myeloma outcomes.

Teddi Mellencamp highlights the vital bond and advocacy of oncology nurses during the 2026 Extraordinary Healer awards ceremony in San Antonio.

Dr. Morvarid Rezaie discusses how oncology nurses can leverage medical cannabis to address polypharmacy and enhance opioid synergy for symptom control.

Dan Silver, PA-C, discusses the importance of early intervention in penile rehabilitation and the APP’s role as a partner in prostate cancer recovery.

CIBMTR data shows manageable toxicity and outpatient potential for liso-cel in R/R MCL, emphasizing the vital role of nursing vigilance and education.

Dan Silver, PA-C, discusses proactive strategies for managing treatment-related erectile dysfunction and penile rehabilitation in prostate cancer.

Deanna Lewis, PA-C, explores how reframing communication as clinical infrastructure fosters trust, psychological safety, and innovation in oncology.

Explore how ctDNA and AI algorithms are optimizing bladder cancer treatment and managing BCG shortages, as discussed at OneOncology APP Symposium.

Larry Bilbrey of Tennessee Oncology explains how AI scribes reduce documentation burden and burnout while improving patient-provider engagement.

Michael Adashek, DO, explores why oncology providers must prioritize cascade testing to protect patients’ families from hereditary cancer risks.

Dr. Joel Neal presents CHRYSALIS-2 data at ASCO 2026, highlighting a 3.5-year median survival and toxicity management for atypical EGFR-mutant NSCLC.

Dr. Sara Tolaney discusses the ASCENT-04 trial results for mTNBC and key strategies for oncology nurses to manage patient toxicities like diarrhea.

ASCO 2026 research highlights GLP-1 medications as a potential breast cancer prevention tool, showing a 30% risk reduction in retrospective analysis.

TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line metastatic TNBC.

At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia.

Camizestrant switch at ESR1 mutation detection improves PFS, patient-reported outcomes, and delays chemotherapy in advanced breast cancer.

Phase III ROSELLA data shows relacorilant plus nab-paclitaxel improves OS in platinum-resistant ovarian cancer with a manageable safety profile.

HR20013 plus dexamethasone improves delayed emesis control and daily functioning for patients on moderately emetogenic chemotherapy in the phase 3 PROTECT trial.

ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m².

Oncology nurses play a vital role in managing cognitive and metabolic toxicities during long-term lorlatinib therapy for ALK+ NSCLC.

New ASCENT-04 data shows sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1+ TNBC regardless of Trop-2, BRCA, or HER2 status.

ASCO 2026: Dr. Shubham Pant discusses managing the unique side effect profile of daraxonrasib, a new standard of care for metastatic pancreatic cancer.

ASCO 2026: The EMERALD-3 study shows adding STRIDE with or without lenvatinib to TACE significantly extends PFS for patients with unresectable HCC.

ASCO 2026: Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab monotherapy.

A large real-world analysis found that higher frailty scores were associated with increased odds of toxicities, hospitalization, and mortality in patients receiving ADC, BiTE, and CAR T-cell therapies.